Abstract
The myelodysplastic syndromes (MDS) are characterized by hemopoietic insufficiency associated with severe cytopenias, leading to serious morbidity, and acute leukemia development. MDS typically occur in elderly people, with a median age at diagnosis ranging between 60 and 75 years. The patients' prognosis, estimated according to the International Prognostic Scoring System, age and performance status should be considered before choosing among the various treatment options. A therapeutic dilemma exists in MDS, due to the multifactorial pathogenetic features of the disease, the heterogeneous stage and the elderly age of patients at diagnosis. This is underlined by the absence of a Food and Drug Administration-approved agent with an indication for this disease. The therapeutic end-points vary from symptom management (using low-intensity treatment with biological targeted agents, or only supportive therapy), to attempts to change the natural history of the disease (generally using high intensity treatment, including intensive chemotherapy and hemopoietic stem cell transplantation). The main goal of low-intensity therapies is generally to induce hematological improvements and is mainly used for low-risk disease. On the other hand, hi...Continue Reading
References
Jul 1, 1979·British Journal of Haematology·M Baccarani, S Tura
Dec 1, 1978·British Journal of Haematology·L Sachs
Aug 1, 1992·British Journal of Haematology·E Hellström-LindbergA Ost
Oct 1, 1992·Annals of Hematology·K B MillerK Kyungmann
Jan 1, 1992·Leukemia Research·C Aul, N Gattermann
Jan 1, 1989·Acta Clinica Belgica·P MineurJ L Michaux
Nov 1, 1989·Cancer·C Aul, W Schneider
Apr 26, 1986·Lancet·A WorsleyT J Hamblin
May 1, 1987·British Journal of Haematology·R E ClarkS A Smith
Jan 1, 1987·Leukemia Research·A D HoW Hunstein
Dec 1, 1986·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B D ChesonM A Friedman
Aug 1, 1985·Cancer·J N WinterK B Miller
Oct 1, 1985·American Journal of Hematology·E P AlessandrinoC Bernasconi
May 26, 1984·Lancet·G T MuftiS M Abidi
Oct 1, 1984·British Journal of Haematology·G TricotR L Verwilghen
Dec 29, 1983·The New England Journal of Medicine·J S WischD W Kufe
Aug 1, 1996·Cancer·S KuriyaY Ishida
Mar 1, 1997·Annals of Hematology·N C Munshi, G J Tricot
Apr 1, 1997·International Journal of Hematology·H OkumuraT Matsuda
Mar 31, 1998·Leukemia·L Busque, D G Gilliland
Jul 25, 1998·Leukemia Research·J E Seng, B A Peterson
Sep 4, 1999·Leukemia Research·L LetendreG Schroeder
Nov 30, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·N L HarrisC D Bloomfield
Sep 1, 2001·British Journal of Haematology·M LübbertA Ferrant
Citations
Apr 25, 2007·Journal of Cancer Research and Clinical Oncology·Hisashi TsurumiHisataka Moriwaki
Sep 10, 2005·Leukemia·H ZwierzinaUNKNOWN EORTC Leukemia Cooperative Group
Jan 12, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Guillermo Garcia-Manero, Pierre Fenaux
Dec 3, 2010·Journal of Clinical and Experimental Hematopathology : JCEH·Junichi KitagawaHisataka Moriwaki
Dec 30, 2009·Leukemia & Lymphoma·Zhijian XiaoTianjiao Zhang
Oct 20, 2010·Leukemia Research·Gail J RobozEric J Feldman
May 11, 2010·Critical Reviews in Oncology/hematology·John F SeymourC L Beach
Dec 2, 2008·Best Practice & Research. Clinical Haematology·Richard M Stone
Nov 15, 2008·Leukemia Research·Anita RyningenOystein Bruserud
Feb 9, 2010·British Journal of Haematology·Pierre FenauxCharles L Beach
Oct 9, 2007·Hematological Oncology·Nobuhiro KanemuraHisataka Moriwaki
Oct 11, 2017·Leukemia Research·Giuseppe VisaniAlessandro Isidori